1. Home
  2. CELC vs CUZ Comparison

CELC vs CUZ Comparison

Compare CELC & CUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$53.29

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Logo Cousins Properties Incorporated

CUZ

Cousins Properties Incorporated

N/A

Current Price

$28.73

Market Cap

4.9B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
CELC
CUZ
Founded
2011
1958
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.9B
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
CELC
CUZ
Price
$53.29
$28.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
11
Target Price
★ $150.85
$33.45
AVG Volume (30 Days)
920.9K
★ 1.4M
Earning Date
11-05-2026
10-29-2026
Dividend Yield
N/A
★ 4.44%
EPS Growth
N/A
★ N/A
EPS
N/A
★ 0.11
Revenue
N/A
★ $993,816,000.00
Revenue This Year
N/A
$6.76
Revenue Next Year
$1,921.71
$2.45
P/E Ratio
★ N/A
$262.18
Revenue Growth
N/A
★ 16.00
52 Week Low
$53.54
$21.03
52 Week High
$151.02
$32.95

Technical Indicators

Market Signals
Indicator
CELC
CUZ
Relative Strength Index (RSI) 30.06 46.72
Support Level N/A $27.31
Resistance Level $72.76 $29.41
Average True Range (ATR) 4.24 0.69
MACD -1.03 -0.13
Stochastic Oscillator 0.16 18.67

Price Performance

Historical Comparison
CELC
CUZ

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

About CUZ Cousins Properties Incorporated

Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.

Share on Social Networks: